Novartis (NVS) Stock Rating Reaffirmed by UBS Group
UBS Group reiterated their neutral rating on shares of Novartis (NYSE:NVS) in a research report report published on Monday morning, www.boersen-zeitung.de reports.
Several other research firms have also weighed in on NVS. JPMorgan Chase & Co. restated a neutral rating on shares of Novartis in a report on Tuesday, September 26th. Zacks Investment Research lowered shares of Novartis from a buy rating to a hold rating in a report on Thursday, September 21st. Leerink Swann lifted their target price on shares of Novartis from $89.00 to $91.00 and gave the company a market perform rating in a report on Monday, October 23rd. Nord/LB restated a neutral rating on shares of Novartis in a report on Tuesday, January 2nd. Finally, Bank of America lowered shares of Novartis from a neutral rating to an underperform rating in a report on Wednesday, December 6th. Five analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $85.32.
Novartis (NVS) traded down $0.47 during trading hours on Monday, hitting $86.41. 1,523,700 shares of the company traded hands, compared to its average volume of 1,071,025. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. The firm has a market cap of $225,650.00, a price-to-earnings ratio of 30.75, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. Novartis has a 1-year low of $69.53 and a 1-year high of $87.29.
A number of hedge funds have recently modified their holdings of the business. WFG Advisors LP increased its position in shares of Novartis by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares during the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Novartis in the 3rd quarter worth about $106,000. Cable Hill Partners LLC increased its position in shares of Novartis by 588.8% in the 3rd quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares during the last quarter. Harding Loevner LP bought a new stake in shares of Novartis in the 2nd quarter worth about $146,000. Finally, Sawyer & Company Inc bought a new stake in shares of Novartis in the 4th quarter worth about $183,000. Hedge funds and other institutional investors own 10.85% of the company’s stock.
Novartis Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.